Literature DB >> 29634631

Counter-Point: Staying Honest When Policy Changes Backfire.

Christine Y Lu1, Gregory Simon2, Stephen B Soumerai1.   

Abstract

Despite the good intentions of the Food and Drug Administration (FDA), many drug warnings are ineffective or have unintended consequences, particularly if the media exaggerates the messages and scares the public. The controversial 2003 to 2004 FDA warnings on youth suicidality associated with antidepressant use are a case in point. In a 10-year interrupted time series (ITS) analysis in 11 health plans, we found that the warnings and hyped media coverage led to substantial reductions in antidepressant use (declines in antidepressant use and overall care corroborated in several studies), and small, visible increases in emergency room and inpatient poisonings with psychotropic drugs. In a gross misunderstanding of the method, Dr Stone calls ITS, "an intuition based upon false analogies, fallacious assumptions and analytical error." We demonstrate visually using published studies that the ITS method is one of the oldest (hundreds of years) and strongest quasi-experimental study designs, and that the alternative data analyses proposed by Dr Stone do not have rates (denominators), nor baselines, so the measures of change are invalid.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29634631      PMCID: PMC5898649          DOI: 10.1097/MLR.0000000000000897

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  32 in total

Review 1.  Evidence of self-report bias in assessing adherence to guidelines.

Authors:  A S Adams; S B Soumerai; J Lomas; D Ross-Degnan
Journal:  Int J Qual Health Care       Date:  1999-06       Impact factor: 2.038

2.  Trends in US emergency department visits for suicide attempts, 1992-2001.

Authors:  Gregory Luke Larkin; Rebecca P Smith; Annette L Beautrais
Journal:  Crisis       Date:  2008

3.  Conflict of Interest and Legal Issues for Investigators and Authors.

Authors:  Joseph P Thornton
Journal:  JAMA       Date:  2017-05-02       Impact factor: 56.272

4.  Characterizing declines in pediatric antidepressant use after new risk disclosures.

Authors:  Susan H Busch; Richard G Frank; Andres Martin; Colleen L Barry
Journal:  Med Care Res Rev       Date:  2010-07-30       Impact factor: 3.929

5.  How complete are E-codes in commercial plan claims databases?

Authors:  Christine Y Lu; Christine Stewart; Ameena T Ahmed; Brian K Ahmedani; Karen Coleman; Laurel A Copeland; Enid M Hunkeler; Matthew D Lakoma; Jeanne M Madden; Robert B Penfold; Donna Rusinak; Fang Zhang; Stephen B Soumerai
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-02       Impact factor: 2.890

6.  Changes in use of lipid-lowering medications among black and white dual enrollees with diabetes transitioning from Medicaid to Medicare Part D drug coverage.

Authors:  Alyce S Adams; Jeanne M Madden; Fang Zhang; Stephen B Soumerai; Dan Gilden; Jennifer Griggs; Connie M Trinacty; Christine Bishop; Dennis Ross-Degnan
Journal:  Med Care       Date:  2014-08       Impact factor: 2.983

7.  Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness.

Authors:  Christine Y Lu; Stephen B Soumerai; Dennis Ross-Degnan; Fang Zhang; Alyce S Adams
Journal:  Med Care       Date:  2010-01       Impact factor: 2.983

8.  Persisting decline in depression treatment after FDA warnings.

Authors:  Anne M Libby; Heather D Orton; Robert J Valuck
Journal:  Arch Gen Psychiatry       Date:  2009-06

9.  Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs.

Authors:  Anne M Libby; David A Brent; Elaine H Morrato; Heather D Orton; Richard Allen; Robert J Valuck
Journal:  Am J Psychiatry       Date:  2007-06       Impact factor: 18.112

10.  False Dichotomies and Health Policy Research Designs: Randomized Trials Are Not Always the Answer.

Authors:  Stephen B Soumerai; Rachel Ceccarelli; Ross Koppel
Journal:  J Gen Intern Med       Date:  2016-10-18       Impact factor: 5.128

View more
  4 in total

1.  Comment on 'Measuring the impact of medicines regulatory interventions - systematic review and methodological considerations' by Goedecke et al.

Authors:  Christine Y Lu; Stephen B Soumerai
Journal:  Br J Clin Pharmacol       Date:  2018-06-22       Impact factor: 4.335

2.  Counter-Point: Early Warning Systems Are Imperfect, but Essential.

Authors:  Christine Y Lu; Gregory Simon; Stephen B Soumerai; Martin Kulldorff
Journal:  Med Care       Date:  2018-05       Impact factor: 2.983

3.  Comparison of Prescribing Patterns Before and After Implementation of a National Policy to Reduce Inappropriate Alprazolam Prescribing in Australia.

Authors:  Andrea L Schaffer; Nicholas A Buckley; Rose Cairns; Sallie Pearson
Journal:  JAMA Netw Open       Date:  2019-09-04

4.  Interrupted time series analysis using autoregressive integrated moving average (ARIMA) models: a guide for evaluating large-scale health interventions.

Authors:  Andrea L Schaffer; Timothy A Dobbins; Sallie-Anne Pearson
Journal:  BMC Med Res Methodol       Date:  2021-03-22       Impact factor: 4.615

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.